IN8BIO, INC. Research and Development Expense
IN8BIO, INC. (INAB) reported Research and Development Expense of $2.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- IN8BIO, INC. research and development expense for the quarter ending 2026-06-30 was $2.49M, a 0.24% increase year-over-year.
- IN8BIO, INC. research and development expense for the quarter ending 2026-03-31 was $2.61M, a 12.08% decline year-over-year.
- IN8BIO, INC. research and development expense for the quarter ending 2025-12-31 was $2.65M, a 26.32% decline year-over-year.
- IN8BIO, INC. research and development expense for the quarter ending 2025-09-30 was $2.10M, a 36.42% decline year-over-year.
- IN8BIO, INC. research and development expense for fiscal 2025 was $10.21M, a 39.80% decline from fiscal 2024.
- IN8BIO, INC. research and development expense for fiscal 2024 was $16.96M, a 0.80% increase from fiscal 2023.
- IN8BIO, INC. research and development expense for fiscal 2023 was $16.83M, a 19.66% increase from fiscal 2022.
- IN8BIO, INC. research and development expense for fiscal 2022 was $14.06M, a 91.40% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.49M 10-Q · filed 2026-08-06 | $5.11M 10-Q · filed 2026-08-06 | $7.75M derived: sum of 3 quarters · filed 2026-08-06 | $9.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.61M 10-Q · filed 2026-05-07 | $5.26M derived: sum of 2 quarters · filed 2026-05-07 | $7.37M derived: sum of 3 quarters · filed 2026-05-07 | $9.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.75M derived: sum of 2 quarters · filed 2026-03-12 | $7.24M derived: sum of 3 quarters · filed 2026-08-06 | $10.21M 10-K · filed 2026-03-12 |
| 2025-09-30 | $2.10M 10-Q · filed 2025-11-06 | $4.59M derived: sum of 2 quarters · filed 2026-08-06 | $7.56M 10-Q · filed 2025-11-06 | $11.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.49M 10-Q · filed 2026-08-06 | $5.46M 10-Q · filed 2026-08-06 | $9.05M derived: sum of 3 quarters · filed 2026-08-06 | $12.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.97M 10-Q · filed 2026-05-07 | $6.57M derived: sum of 2 quarters · filed 2026-05-07 | $9.88M derived: sum of 3 quarters · filed 2026-05-07 | $15.03M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $6.90M derived: sum of 2 quarters · filed 2026-03-12 | $12.06M derived: sum of 3 quarters · filed 2026-03-12 | $16.96M 10-K · filed 2026-03-12 |
| 2024-09-30 | $3.31M 10-Q · filed 2025-11-06 | $8.46M derived: sum of 2 quarters · filed 2025-11-06 | $13.37M 10-Q · filed 2025-11-06 | $17.89M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $5.16M 10-Q · filed 2025-08-07 | $10.06M 10-Q · filed 2025-08-07 | $14.58M derived: sum of 3 quarters · filed 2025-08-07 | $18.37M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $4.90M 10-Q · filed 2025-05-07 | $9.43M derived: sum of 2 quarters · filed 2025-05-07 | $13.21M derived: sum of 3 quarters · filed 2025-05-07 | $17.34M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $8.31M derived: sum of 2 quarters · filed 2025-03-13 | $12.44M derived: sum of 3 quarters · filed 2025-03-13 | $16.83M 10-K · filed 2025-03-13 |
| 2023-09-30 | $3.79M 10-Q · filed 2024-11-12 | $7.92M derived: sum of 2 quarters · filed 2024-11-12 | $12.30M 10-Q · filed 2024-11-12 | $16.23M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $4.13M 10-Q · filed 2024-08-08 | $8.52M 10-Q · filed 2024-08-08 | $12.44M derived: sum of 3 quarters · filed 2024-08-08 | $16.70M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.38M 10-Q · filed 2024-05-09 | $8.31M derived: sum of 2 quarters · filed 2024-05-09 | $12.56M derived: sum of 3 quarters · filed 2024-05-09 | $16.07M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $8.18M derived: sum of 2 quarters · filed 2024-03-14 | $11.68M derived: sum of 3 quarters · filed 2024-03-14 | $14.06M 10-K · filed 2024-03-14 |
| 2022-09-30 | $4.25M 10-Q · filed 2023-11-09 | $7.76M derived: sum of 2 quarters · filed 2023-11-09 | $10.14M 10-Q · filed 2023-11-09 | $12.83M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $3.50M 10-Q · filed 2023-08-10 | $5.88M 10-Q · filed 2023-08-10 | $8.57M derived: sum of 3 quarters · filed 2023-08-10 | $9.92M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $2.38M 10-Q · filed 2023-05-12 | $5.07M derived: sum of 2 quarters · filed 2023-05-12 | $6.42M derived: sum of 3 quarters · filed 2023-05-12 | $8.48M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $4.04M derived: sum of 2 quarters · filed 2023-03-30 | $6.10M derived: sum of 3 quarters · filed 2023-03-30 | $7.35M 10-K · filed 2023-03-30 |
| 2021-09-30 | $1.35M 10-Q · filed 2022-11-10 | $3.41M derived: sum of 2 quarters · filed 2022-11-10 | $4.66M 10-Q · filed 2022-11-10 | $6.14M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $2.06M 10-Q · filed 2022-08-12 | $3.31M 10-Q · filed 2022-08-12 | $4.79M derived: sum of 3 quarters · filed 2022-08-12 | $5.85M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $1.25M 10-Q · filed 2022-05-12 | $2.73M derived: sum of 2 quarters · filed 2022-05-12 | $3.79M derived: sum of 3 quarters · filed 2022-05-12 | $5.57M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $2.54M derived: sum of 2 quarters · filed 2022-03-17 | $4.33M derived: sum of 3 quarters · filed 2022-03-17 | $5.38M 10-K · filed 2022-03-17 |
| 2020-09-30 | $1.06M 10-Q · filed 2021-11-10 | $2.84M derived: sum of 2 quarters · filed 2021-11-10 | $3.89M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $1.78M 10-Q · filed 2021-09-10 | $2.84M 10-Q · filed 2021-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |